Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.
Also called NCT02270736
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 256 participants
- Sponsor
- Merz Pharmaceuticals GmbH
- Registry
-
NCT02270736 -
2013-004532-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Georgia, Hungary, Poland, Russia, Serbia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02270736. Randomized; double masking; primary purpose treatment. Start 2015-02-09 (actual); primary completion 2018-02-23 (actual). Results posted on 2021-01-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
- Acronym
- SIPEXI
- Condition
- Chronic Troublesome Sialorrhea
- Condition
- Cerebral Palsy
- Condition
- Stroke
- Condition
- Traumatic Brain Injury
- Condition
- Intellectual Disability
- Intervention (Drug)
- NT 201 Placebo
- Intervention (Drug)
- NT 201
- Lead sponsor
- Merz Pharmaceuticals GmbH
Record details
- Record id
cardio:ct-nct02270736- Content hash
1388c4774833f67c2fffe54ba22776a9ae3602523751247471e0d65e6c76e7bc